MR图像引导聚焦超声破坏血脑/血肿瘤屏障后小鼠胶质母细胞瘤免疫景观分析
研究在小鼠GL261原位胶质母细胞瘤模型中,用聚焦超声联合微泡破坏血脑/血肿瘤屏障,观察对先天性和适应性免疫的影响。超声后树突状细胞数量在肿瘤和引流颈部淋巴结显著升高,CD8+T细胞频率未显著改变但1周时上调检查点分子,2周时出现适应性耐药机制如CD4+T细胞TIGIT和非免疫细胞CD155上调。作者认为该屏障破坏具有轻度、短暂炎症效应,与靶向适应性耐药的辅助策略联合可能改善结局。
要点
- 聚焦超声联合微泡破坏血脑/血肿瘤屏障后,小鼠GL261肿瘤和引流颈部淋巴结中树突状细胞数量显著升高。
- 0.6 MPa聚焦超声后CD86+树突状细胞频率上调,提示成熟度增加。
- 聚焦超声未显著改变CD8+T细胞频率,但1周后检查点分子上调,2周后CD4+T细胞TIGIT和非免疫细胞CD155上调,提示适应性耐药出现。
核心结论
- 聚焦超声破坏血脑/血肿瘤屏障在胶质瘤中产生轻度、短暂的炎症效应,提示与靶向适应性耐药的辅助治疗策略联合可能改善结局。
研究设计与样本
- 研究为小鼠GL261原位胶质母细胞瘤模型,静脉注射微泡后接受聚焦超声破坏血脑/血肿瘤屏障(1.1 MHz、0.5 Hz脉冲重复频率、10 ms bursts、0.4-0.6 MPa),超声后1-2周取脑、脑膜和外周淋巴器官行流式细胞术检测。
主要发现
- 聚焦超声后GL261肿瘤和引流颈部淋巴结中树突状细胞数量显著升高。
- 0.6 MPa聚焦超声后CD86+树突状细胞频率上调。
- 聚焦超声未显著改变所评估器官中CD8+T细胞频率,但这些细胞在超声后1周上调检查点分子。
- 超声后2周观察到适应性耐药机制出现,包括CD4+T细胞上TIGIT上调和非免疫肿瘤及基质细胞上CD155上调。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma (GB) poses formidable challenges to systemic immunotherapy approaches owing to the paucity of immune infiltration and presence of the blood brain/tumor barriers (BBB/BTB). We hypothesize that BBB/BTB disruption (BBB/BTB-D) with focused ultrasound (FUS) and microbubbles (MB) increases immune infiltration in GB. As a prelude to rational combination of FUS with ITx, we herein investigate the impact of localized BBB/BTB-D on innate and adaptive immune responses in an orthotopic murine GB model. METHODS: Mice with GL261 gliomas received i.v. MB and underwent FUS BBB/BTB-D (1.1 MHz, 0.5 Hz pulse repetition frequency, 10 ms bursts, 0.4-0.6 MPa). Brains, meninges, and peripheral lymphoid organs were excised and examined by flow cytometry 1-2 weeks following FUS. RESULTS: The number of dendritic cells (DC) was significantly elevated in GL261 tumors and draining cervical LN in response to sonication. CD86 + DC frequency was also upregulated with 0.6 MPa FUS, suggesting increased maturity. While FUS did not significantly alter CD8 + T cell frequency across evaluated organs, these cells upregulated checkpoint molecules at 1 week post-FUS, suggesting increased activation. By 2 weeks post-FUS, we noted emergence of adaptive resistance mechanisms, including upregulation of TIGIT on CD4 + T cells and CD155 on non-immune tumor and stromal cells. CONCLUSIONS: FUS BBB/BTB-D exerts mild, transient inflammatory effects in gliomas-suggesting that its combination with adjunct therapeutic strategies targeting adaptive resistance may improve outcomes. The potential for FUS-mediated BBB/BTB-D to modify immunological signatures is a timely and important consideration for ongoing clinical trials investigating this regimen in GB.
引用
- Sheybani ND, Witter AR, Garrison WJ, et al. Profiling of the immune landscape in murine glioblastoma following blood brain/tumor barrier disruption with MR image-guided focused ultrasound. J Neurooncol. 2021. PMID: 34734364. doi:10.1007/s11060-021-03887-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。